Aurdan Capital Management LLC Takes Position in Eli Lilly and Company (NYSE:LLY)

Aurdan Capital Management LLC purchased a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 606 shares of the company's stock, valued at approximately $468,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Grassi Investment Management boosted its stake in Eli Lilly and Company by 0.3% during the fourth quarter. Grassi Investment Management now owns 79,512 shares of the company's stock valued at $61,383,000 after buying an additional 225 shares during the last quarter. Elevate Capital Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $262,000. Capital & Planning LLC lifted its stake in shares of Eli Lilly and Company by 15.6% in the 4th quarter. Capital & Planning LLC now owns 481 shares of the company's stock valued at $371,000 after purchasing an additional 65 shares during the last quarter. Garner Asset Management Corp lifted its stake in shares of Eli Lilly and Company by 2.3% in the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company's stock valued at $411,000 after purchasing an additional 12 shares during the last quarter. Finally, Finley Financial LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $311,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 0.9%

NYSE LLY traded down $6.63 on Wednesday, reaching $718.59. 2,929,417 shares of the stock traded hands, compared to its average volume of 3,620,321. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The company has a fifty day moving average price of $784.45 and a 200-day moving average price of $801.86. The company has a market cap of $681.03 billion, a price-to-earnings ratio of 61.37, a PEG ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the previous year, the firm posted $2.58 earnings per share. The company's revenue was up 45.2% on a year-over-year basis. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.83%. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Analysts Set New Price Targets

LLY has been the subject of several analyst reports. Citigroup lowered their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price target for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Finally, Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $1,011.37.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.13% of the stock is owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.